SMTL ID : 7r7k.1

Structure of Human Anaplastic Lymphoma Kinase Domain in complex with (4-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]isoindolin-1-one)

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.83 Å

Oligo State

monomer

Ligands

1 x 25J: 4-(6-amino-5-{(1R)-1-[5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one(Non-covalent)

25J.1: 19 residues within 4Å: Chain A: L.38, G.39, H.40, V.46, A.64, K.66, V.96, L.112, E.113, L.114, M.115, A.116, G.118, D.119, R.169, N.170, L.172, G.185, D.186 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:L.38, A:L.172, A:L.172 Hydrogen bonds: A:E.113, A:M.115 Water bridges: A:E.48 Halogen bonds: A:N.170

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Shiba-Ishii, A. et al., Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer (2022)

Release Date

2022-06-29

Peptides

ALK tyrosine kinase receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK tyrosine kinase receptor

Related Entries With Identical Sequence